Navigation Links
FDA funds pediatric trial testing genetically reprogrammed HSV to treat cancer
Date:10/12/2010

to attack cancer cells in other ways such as activating certain types of chemotherapies in a one-two punch or destroying blood vessels that feed tumors. Research in mouse models of human cancer by Cripe's laboratory has shown oncolytic HSV agents to be effective at shrinking a variety of modeled tumor types, suggesting a possible approach for treating human disease.

"Our goal in the current HSV1716 trial is to light a fire to the cancer so that the virus replicates and spreads to the cancer cells," Dr. Cripe explained. "We have to take this one step at a time and the initial phase of the trial focuses on making sure the virus doesn't cause adverse side effects. It has been tested in Europe in adults with brain cancer, squamous cell carcinoma and melanoma and shown in those trials to be safe."

HSV1716 has also been tested extensively for safety in animal models at Cincinnati Children's Hospital by Dr. Cripe and in Europe prior to it being tested in people.

The Phase I trial will include up to 18 patients and is expected to last three years. The optimum safe dosing for this virus is unknown, so the study will sequentially increase dosing levels in small groups of patients and observe for side effects as the trial proceeds. This earliest phase tests the lowest dose on older children and young adults with solid tumor cancers who have limited or no standard therapy options available.

The researchers plan to add younger patients with earlier stages of cancer as the trial proceeds. They will not be able to determine if the safety trial is successful until all patients have received treatment and the results analyzed. As with all clinical trials of new anticancer therapies in patients, many factors can influence the risk for severe side effects and anticancer activity. Even though HSV1716 may cause tumor shrinkage in mouse models of pediatric cancer, it may not have antitumor effect in patients.


'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. NIH funds Center of Excellence for Molecular Hematology at Cincinnati Childrens
2. $1.5M grant funds research aimed at reducing strokes in children with sickle cell disease
3. NIH funds center at Arizona State to battle infectious diseases
4. French national research agency funds PREDIMOL project
5. NHGRI funds development of third generation DNA sequencing technologies
6. $22.5 million grant funds international study of membrane proteins
7. NSF funds innovative approach to biomimetic nanofiber bone regeneration
8. Gulf oil spill: NSF funds research on impacts to Florida Everglades
9. NSF funds Virginia Tech program to train researchers at intersection of engineering, biology
10. NIH funds multicenter glue grant to study enzyme function
11. California funds UCI basic research on stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
(Date:2/5/2015)... , Feb. 3, 2015 Despite ... demand from industries such as consumer electronics, automotive, ... for surface mount technology (SMT) screen printers. Innovations ... automatic control will push the adoption curve up. ... remain steady as glue dispensers are indispensable in ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... ALAMOS, New Mexico, June 22, 2011 Los Alamos National ... R&D100 Awards. Recognized as the "Oscars of Invention" by ... proven technological advances of the past year. The winning ... nucleic acids, a spacer fluid for oil wells that ...
... generated by the expanding local foods movement, demand ... States. The fresh market strawberry industry in the ... weather conditions and long growing seasons. Even with ... in other areas of the country, particularly near ...
... INPlant growth retardants, or PGRs, are used in greenhouse ... PGRs can be applied using a variety of methods, ... Research has shown that drenches provide more uniform results ... but the efficacy of drenches can be affected by ...
Cached Biology News:Los Alamos National Laboratory earns 3 R&D 100 Awards 2Los Alamos National Laboratory earns 3 R&D 100 Awards 3Early-season strawberry tested in high elevation conditions 2Plant growth rate, stem length unaffected by rice hull, peat substrate 2
(Date:3/4/2015)... 04, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Biomarkers - Technologies, ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:3/4/2015)... Calif. , March 4, 2015 ... a specialty pharmaceutical company focused on the development ... of acute and breakthrough pain, today announced that ... financial results after market close on Monday, March ... conference call at 4:30 p.m. Eastern Time (1:30 ...
(Date:3/4/2015)... March 4, 2015 ... Paris en décembre 2011, l,étude ...   », qui compare   l es ...   sorafénib dans le carcinome hépatocellulaire avancé, a ... du foie avancé   ; les résultats sont ...
(Date:3/3/2015)... Experts and industry insiders from around the world ... REBELation exploring innovation, inspiration and world-changing ideas in Lexington, ... year, Alltech’s annual international conference traditionally draws more than ... join the REBELation at an extra discount registration closes ... which point the standard early registration rate will apply. ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... GOTHENBURG, Sweden, July 22 ... and drug discovery,today announced its collaboration with University of ... Cellaxess(R)HT, the world,s first,system for high throughput transfection enabling ... To view the Multimedia News Release, ...
... , ROCKVILLE, Md., July 22 Human Genome Sciences, ... Government has exercised its option to purchase an additional 45,000 doses ... over a three-year period, beginning near the end of 2009. ... deliveries are completed. , , ...
... The hallmark of ... will not affect patient care", but the question remains: how many more people can be ... as announcing an increase of more than 20,000 jobs in health care. , ... Seattle, WA (Vocus) July 22, 2009 -- ...
Cached Biology Technology:University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer 2Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government 2Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government 3Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government 4Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government 5Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government 6The MedZilla Report: June 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: June 2009 Employment Outlook for Biotech/Pharma/Health 3